Consensus lacking on ‘value’ for new anticancer drugs
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesEuropePharmaceuticalsProduct LifecycleRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesEuropePharmaceuticalsProduct Lifecycle